Market Research Logo

Global Intravenous (IV) Iron Drugs Market Report: 2016 Edition

Global Intravenous (IV) Iron Drugs Market Report: 2016 Edition

Iron is vital for multiple bodily functions, most importantly for the production of hemoglobin for red blood cells which are responsible for transporting oxygen in the blood. As an element, the only source of iron is from the diet. There is no way the body can produce iron itself. Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.

The report analyzes the global iron products industry along with an extensive coverage of global, Europe and the US I.V. iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.


1. Iron in Human Body: An Introduction
1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
Table A: Risk Factors for CKD
1.2 Iron Deficiency - Anemia
1.2.1 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment
1.4 Types of I.V. Iron
2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
Table 1: Global Iron Product Market by Value (2011-2015)
2.2 Global Iron Products Market Share by Segment
Table 2: Global Iron Products Market Share by Segment (2015)
3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value
Table 3: Global I.V. Iron Drugs Market by Value (2010-2015)
3.2 Global I.V. Iron Drugs Market by Product
Table 4: Global I.V. Iron Drugs Market by Product (2010-2015)
3.3 Global I.V. Iron Drugs Market Share by Product
Table 5: Global I.V. Iron Drugs Market Share by Product (2015)
4. I.V. Iron Drugs Regional Market Analysis
4.1 European I.V. Iron Drug Market
4.1.1 European I.V. Iron Drug Market by Value
Table 6: European I.V. Iron Drug Market by Value (2010-2015)
4.1.2 European I.V. Iron Drug Market by Product
Table 7: European I.V. Iron Drug Market by Product (2010-2015)
4.1.3 European I.V. Iron Drug Market Share by Product
Table 8: European I.V. Iron Drug Market Share by Product (2015)
4.2 The US I.V. Iron Drug Market
4.2.1 The US I.V. Iron Drug Market by Value
Table 9: The US I.V. Iron Drug Market by Value (2010-2015)
4.2.2 The US I.V. Iron Drug Market by Product
Table 10: The US I.V. Iron Drug Market by Product (2010-2015)
4.2.3 The US I.V. Iron Drug Market Share by Product
Table 11: The US I.V. Iron Drug Market Share by Product (2015)
4.2.4 The US Non-dialysis I.V. Iron Drug Market by Volume
Table 12: The US Non-dialysis I.V. Iron Drug Market Volume (2010-2015)
4.2.5 The US Non-dialysis I.V. Iron Drug Market Share by Product
Table 13: The US Non-dialysis I.V. Iron Drug Market Share by Product (2015)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increase in Number of Dialysis Cases
Table 14: Global Dialysis Patient Population (2007-2015E)
Table 15: Global Dialysis Patients by Type (2014)
5.1.2 Increasing Healthcare Expenditure
Table 16: Global Health Care Expenditure Per Capita (2007-2015E)
Table 17: The US Healthcare Expenditure Per Capita (2007-2015E)
5.1.3 Increasing Cases of CKD and ESRD
5.1.4 Rising Ageing Population
Table 18: Global Ageing Population (2006-2015E)
5.1.5 Shift from Rural to Urban Regions
Table 19: Global Urban Population (2007-2015E)
5.1.6 Prevalence of Iron Deficiency in Women
Table 20: Prevalence of Iron Deficiency in Women in the US
Table 21: The US Female Population (2007-2015E)
5.1.7 Increasing Life Expectancy Rate
Table 22: Global Life Expectancy Rate (2007-2015E)
5.1.8 Rising Medicines Expenditures
Table 23: Global Spending on Medicines (2010-2020E)
Table 24: The US Spending on Medicine (2007-2015)
5.1.9 Growing Number of ERSD Patients
Table 25: Global ERSD Patients (2009-2020E)
5.2 Trends
5.2.1 New Product Development
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.2.3 Feraccru Treatment Penetration
Table 26: Global Addressable Patients for Feraccru by Underlying Disease - Developed World
5.3 Challenges
5.3.1 Emerging Anemia Management Therapies
Table B: Emerging Non-Intravenous Therapies for Anemia Management
5.3.2 Potential Risks of I.V. Iron
6. Competitive Landscape
6.1 Product Comparison
Table C: Comparison between Injectafer® and Venofer®
Table D: Summary of Feraccru vs. IV Iron Profile
7. Company Profiles
7.1 Galenica group
7.1.1 Business Overview
Table 27: Galenica’s Net Sales Share by Business Segments (2015)
Table 28: Galenica’s Net Sales Share by Region (2015)
7.1.2 Financial Overview
Table 29: Galenica’s Net Sales and Net Profit (2011-2015)
7.1.3 Business Strategies
7.2 AMAG Pharmaceuticals
7.2.1 Business Overview
7.2.2 Financial Overview
Table 30: AMAG Pharmaceuticals’ Revenue and Net Income (2011-2015)
7.2.3 Business Strategies
7.3 Allergan plc.
7.3.1 Business Overview
Table 31: Allergan Plc.’s Net Sales Business Segment (2015)
7.3.2 Financial Overview
Table 32: Allergan Plc.’s Revenue and Net Income (2011-2015)
7.3.3 Business Strategies
8. Market Outlook
8.1 Market Forecast
Table 33: Global I.V. Iron Drug Market Forecast (2014-2019E)
8.2 Forecast Methodology
Table E: Dependent & Independent Variables (2011-2015)
8.2.1 Dependent and Independent Variables
8.2.2 Correlation Analysis
Table F: Correlation Matrix
8.2.3 Regression Analysis
Table G: Model Summary – Coefficient of Determination
Table H: Regression Coefficients Output

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report